These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 28668883

  • 21. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, Lewis KB, Ecsedy J, Washington K, Beauchamp RD, El-Rifai W.
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [Abstract] [Full Text] [Related]

  • 22. Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway.
    Seo H, Song J, Kim M, Han DW, Park HJ, Song M.
    Nutrients; 2018 Dec 21; 11(1):. PubMed ID: 30577618
    [Abstract] [Full Text] [Related]

  • 23. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
    Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S.
    Oncotarget; 2014 May 15; 5(9):2807-19. PubMed ID: 24798549
    [Abstract] [Full Text] [Related]

  • 24. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q, Gu L, Liao S, Zheng Y, Zhang S, Cao Y, Zhang J, Wang Y.
    Apoptosis; 2019 Feb 15; 24(1-2):83-94. PubMed ID: 30515612
    [Abstract] [Full Text] [Related]

  • 25. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
    Camaj P, Primo S, Wang Y, Heinemann V, Zhao Y, Laubender RP, Stintzing S, Giessen-Jung C, Jung A, Gamba S, Bruns CJ, Modest DP.
    Future Oncol; 2015 Feb 15; 11(13):1919-29. PubMed ID: 26161928
    [Abstract] [Full Text] [Related]

  • 26. γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules.
    Prasad S, Gupta SC, Tyagi AK, Aggarwal BB.
    Br J Cancer; 2016 Sep 27; 115(7):814-24. PubMed ID: 27575851
    [Abstract] [Full Text] [Related]

  • 27. Modulating Pluripotency Network Genes with Omega-3 DHA is followed by Caspase- 3 Activation and Apoptosis in DNA Mismatch Repair-Deficient/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
    Mahmoudi N, Delirezh N, Sam MR.
    Anticancer Agents Med Chem; 2020 Sep 27; 20(10):1221-1232. PubMed ID: 32116204
    [Abstract] [Full Text] [Related]

  • 28. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
    Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S.
    Anticancer Res; 2011 Jul 27; 31(7):2535-9. PubMed ID: 21873171
    [Abstract] [Full Text] [Related]

  • 29. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
    Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI, Dalgleish AG.
    Cancer Res; 2003 Feb 01; 63(3):593-9. PubMed ID: 12566301
    [Abstract] [Full Text] [Related]

  • 30. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.
    Zhong L, Wang R, Wang Y, Peng S, Ma Y, Ding S, Yang H, Chen S, Luo X, Wang W.
    Neoplasia; 2020 Sep 01; 22(9):365-375. PubMed ID: 32629177
    [Abstract] [Full Text] [Related]

  • 31. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, Anders R, Karagkounis G, Choti MA, Pawlik TM.
    JAMA Surg; 2015 Aug 01; 150(8):722-9. PubMed ID: 26038887
    [Abstract] [Full Text] [Related]

  • 32. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH, Truxius DC, Vogel HA, Harizanova J, Murarka S, Martín-Gago P, Bastiaens PIH.
    Int J Cancer; 2019 Feb 15; 144(4):767-776. PubMed ID: 30194764
    [Abstract] [Full Text] [Related]

  • 33. Gambogic acid induces apoptosis and inhibits colorectal tumor growth via mitochondrial pathways.
    Huang GM, Sun Y, Ge X, Wan X, Li CB.
    World J Gastroenterol; 2015 May 28; 21(20):6194-205. PubMed ID: 26034354
    [Abstract] [Full Text] [Related]

  • 34. Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.
    Jiffry J, Thavornwatanayong T, Rao D, Fogel EJ, Saytoo D, Nahata R, Guzik H, Chaudhary I, Augustine T, Goel S, Maitra R.
    Clin Cancer Res; 2021 Feb 01; 27(3):865-876. PubMed ID: 33168658
    [Abstract] [Full Text] [Related]

  • 35. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C.
    Clin Cancer Res; 2015 Mar 15; 21(6):1383-94. PubMed ID: 25589625
    [Abstract] [Full Text] [Related]

  • 36. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
    Iskandar K, Rezlan M, Yadav SK, Foo CH, Sethi G, Qiang Y, Bellot GL, Pervaiz S.
    Antioxid Redox Signal; 2016 May 10; 24(14):781-94. PubMed ID: 26714745
    [Abstract] [Full Text] [Related]

  • 37. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
    Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, Wolf CR, Smith G.
    Br J Cancer; 2015 Apr 28; 112(9):1480-90. PubMed ID: 25919696
    [Abstract] [Full Text] [Related]

  • 38. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH, Leung WH, Pang YJ, Hsu HH.
    Oncol Rep; 2016 Jan 28; 35(1):107-16. PubMed ID: 26496897
    [Abstract] [Full Text] [Related]

  • 39. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
    Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Li Z, Zhou D.
    PLoS One; 2014 Jan 28; 9(11):e113186. PubMed ID: 25427200
    [Abstract] [Full Text] [Related]

  • 40. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer.
    Ye WL, Huang L, Yang XQ, Wan S, Gan WJ, Yang Y, He XS, Liu F, Guo X, Liu YX, Hu G, Li XM, Shi WY, He K, Wu YY, Wu WX, Lu JH, Song Y, Qu CJ, Wu H.
    Proc Natl Acad Sci U S A; 2024 Oct 15; 121(42):e2406936121. PubMed ID: 39388269
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.